Efficacy of Neoadjuvant Chemotherapy Combined with Bevacizumab Versus Neoadjuvant Chemotherapy Alone for Her2-negative Breast Cancer:A Meta-Analysis of Randomized ;controlled Clinical Trials

Rui Han,Guanying Wang,Yujiao Zhang,Xinhan Zhao

DOI: https://doi.org/10.3785/j.issn.1008-9292.2016.07.08

2016-01-01

Abstract:Objective: To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer.Methods: We searched PubMed, the Cochrane Library, Web of Science, CNKI, Wanfang Database and the abstracts of major international conferences in recent 5 years to identify prospective randomized controlled clinical trials that met the inclusion and exclusion criteria. Study selection and analyses were undertaken according to the Cochrane Handbook.Meta-analysis was performed using RevMan 5.3 software.Results: Six trials were identified with 4440 eligible patients. The results of this meta-analysis showed that the rate of pathological complete response ( pCR ) was higher in Her-2 negative breast cancer patients receiving bevacizumab combined with neoadjuvant chemotherapy than that in patients with neoadjuvant chemotherapy alone (24.7% vs 20.1%, RR =1.23, 95%CI: 1.10 -1.37, P <0.01) .In addition, the pCR rate rose up when bevacizumab was added to neoadjuvant chemotherapy both in hormone receptor-positive patients ( 13 .1% vs 10 .2%, RR =1.28, 95%CI: 1.04 -1.58, P <0.05 ) and in hormone receptor-negative patients (46.3% vs 37.1%, RR=1.25, 95%CI: 1.12 -1.39, P <0.01).Statistical differences were observed in the rate of relevant adverse events such as hypertention (3.2%vs 0.6%, RR=5.292, 95%CI:2.933 -9.549, P<0.01 ) and mucositis (10.5%vs 2.0%, RR=5.340, 95%CI:3.743 -7.617, P<0.01) between the combination group and the chemotherapy alone group.Differences in other toxicities such as febrile neutropenia, infection, surgical complications, neutropenia and hand-foot syndrome were also found to be statistically significant between the combination group and the chemotherapy alone group ( all P <0 .05 ) , while such difference was not found in the occurrence of peripheral neuropathy ( P >0.05 ) . Conclusion: The addition of bevacizumab to neoadjuvant chemotherapy in Her2-negative breast cancer can significantly improve pathological complete response, but may bring more grade 3 and 4 toxicities.More neoadjuvant trials need to be done to define subgroups of Her2-negative breast cancer that would have clinically significant long-term benefit from bevacizumab treatment.